Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 31, 2026

A High-throughput, High-content, Liquid-based C. elegans Pathosystem
09:44

A High-throughput, High-content, Liquid-based C. elegans Pathosystem

Published on: July 1, 2018

Using C. elegans for antimicrobial drug discovery.

Athanasios Desalermos1, Maged Muhammed, Justin Glavis-Bloom

  • 1Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.

Expert Opinion on Drug Discovery
|June 21, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prolonged Neurological Depression, Bradycardia, and Gastroparesis Following Acute Oral Cannabinoid Ingestion: A Case Report.

Cureus·2026
Same author

Effect of Early Administration of Casirivimab and Imdevimab in Hospitalized Patients with COVID-19: A Post Hoc Analysis.

Infection and drug resistance·2026
Same author

Real-world clinical outcomes of macrophage activation-like syndrome and hyperferritinemia in sepsis: a retrospective database analysis.

EClinicalMedicine·2026
Same author

Overcoming the energy-dependent barrier to aminoglycoside uptake: multimodal strategies to sensitize <i>Staphylococcus aureus</i> persisters.

Microbiology and molecular biology reviews : MMBR·2026
Same author

In outpatients with COVID-19 during Omicron variant circulation, some antivirals reduce time to recovery.

Annals of internal medicine·2026
Same author

Effects of Tirzepatide on Body Composition, Metabolic Parameters, and Sleep Outcomes: A Real-World One-Year Prospective Study.

Cureus·2026
Same journal

Why Next-generation mechanistic models Will transform drug discovery: integrating efficacy and safety.

Expert opinion on drug discovery·2026
Same journal

Toward a nuanced framework for the medical development of ibogaine and its analogues and derivatives: implications for psychopharmacology.

Expert opinion on drug discovery·2026
Same journal

From mitochondrial signal to discovery decision: a reserve-demand framework for translational risk assessment.

Expert opinion on drug discovery·2026
Same journal

Advances in 3D cell culture models for alzheimer's disease drug discovery.

Expert opinion on drug discovery·2026
Same journal

Are patient-derived models of amyotrophic lateral sclerosis a game changer for novel drug discovery?

Expert opinion on drug discovery·2026
Same journal

Unfolding prion misfolding and the challenge of identifying effective therapeutics: is there hope on the horizon?

Expert opinion on drug discovery·2026
See all related articles

The microscopic nematode Caenorhabditis elegans (C. elegans) offers a promising model for discovering new antimicrobial drugs to combat rising antimicrobial resistance. Its use in high-throughput screening accelerates the identification of novel, non-toxic compounds.

Area of Science:

  • Microbiology
  • Drug Discovery
  • Nematology

Background:

  • Increasing antimicrobial resistance necessitates novel therapeutic agents.
  • Microbial pathogenesis research requires efficient screening models.
  • Caenorhabditis elegans (C. elegans) emerges as a valuable model organism.

Purpose of the Study:

  • To review the utility of C. elegans as a model host for studying microbial pathogenesis.
  • To highlight C. elegans' role in accelerating antimicrobial drug discovery.
  • To discuss the advantages and limitations of using C. elegans in drug development.

Main Methods:

  • Review of recent literature on C. elegans in microbial pathogenesis and drug discovery.
  • Exploration of high-throughput screening methodologies using C. elegans.

More Related Videos

Quantitative and Automated High-throughput Genome-wide RNAi Screens in C. elegans
10:58

Quantitative and Automated High-throughput Genome-wide RNAi Screens in C. elegans

Published on: February 27, 2012

The Nematode Caenorhabditis Elegans - A Versatile In Vivo Model to Study Host-microbe Interactions
11:58

The Nematode Caenorhabditis Elegans - A Versatile In Vivo Model to Study Host-microbe Interactions

Published on: October 18, 2017

Related Experiment Videos

Last Updated: May 31, 2026

A High-throughput, High-content, Liquid-based C. elegans Pathosystem
09:44

A High-throughput, High-content, Liquid-based C. elegans Pathosystem

Published on: July 1, 2018

Quantitative and Automated High-throughput Genome-wide RNAi Screens in C. elegans
10:58

Quantitative and Automated High-throughput Genome-wide RNAi Screens in C. elegans

Published on: February 27, 2012

The Nematode Caenorhabditis Elegans - A Versatile In Vivo Model to Study Host-microbe Interactions
11:58

The Nematode Caenorhabditis Elegans - A Versatile In Vivo Model to Study Host-microbe Interactions

Published on: October 18, 2017

  • Comparative analysis of C. elegans as a model versus mammalian systems.

    • Main Results:

    • C. elegans facilitates in vivo drug discovery through high-throughput screening of chemical libraries.
    • The nematode model aids in researching various diseases, including fungal infections.
    • Significant differences exist between C. elegans and mammalian models, impacting result interpretation.

    Conclusions:

    • C. elegans presents a promising, albeit imperfect, model for novel antimicrobial drug discovery.
    • Ongoing research aims to refine C. elegans-based methodologies for improved drug development.
    • The field of C. elegans-driven antimicrobial discovery is expanding rapidly.